αs1-casein blood-pressure peptide
A natural peptide fragment that blocks ACE, the enzyme that raises blood pressure, helping to lower it; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Literature-extracted sequence peptide — synthesized for bioassay as documented in linked reference(s)
Fork this card to add platform evidence →
Activity measured in linked reference(s) — IC50/MIC/cytotoxicity data
Fork this card to add platform evidence →
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could a natural peptide from milk block blood pressure in a smarter, more targeted way than standard medications?
Common ACE-inhibitor drugs (like lisinopril) trigger a persistent dry cough in roughly 1 in 5 users because they block two related enzymes at once. If this peptide turns out to target only the one enzyme responsible for blood pressure control, it could offer a gentler option for the millions of people who stop taking their medication because of that cough.
What if a food peptide helps your blood pressure by changing what lives in your gut, not by blocking an enzyme?
If this mechanism holds, the peptide would work through a completely different route than any current blood pressure drug, potentially explaining why benefits in studies appeared slowly and lasted longer. For people looking for a food-based or probiotic-friendly approach to blood pressure support, that would open a genuinely new door.
Does this peptide get destroyed in your stomach before it can do anything useful, or does enough survive to matter?
Most peptides are broken down in the gut before they can reach the bloodstream, which limits them to local effects. If this one makes it through largely intact, it could potentially be developed as an oral supplement or even a drug, rather than being limited to food and probiotic applications. That distinction shapes the entire development path.
Could one naturally occurring peptide do the job of two different blood pressure medications at the same time?
A drug called sacubitril/valsartan already proves that blocking two specific enzymes together lowers blood pressure better than blocking just one, but it is a prescription combination drug. If this milk peptide could do something similar on its own, it might one day offer a food-derived ingredient with an amplified effect and a naturally low toxicity profile. This is speculative: no one has tested this peptide against the second enzyme yet.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.59074866771698 | boltz-2 |
| ranking score | 0.7434992790222168 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 2.073 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04597,
sequence = {FVAPFPEVFGK},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}